A61K31/606

Pharmaceutical formulation for the treatment of inflammatory changes to the rectum

Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.

Pharmaceutical formulation for the treatment of inflammatory changes to the rectum

Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.

Pharmaceutical formulation for the treatment of inflammatory changes to the rectum

Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.

PROBIOTIC BIOFILM COMPOSITIONS AND METHODS OF PREPARING SAME
20220154134 · 2022-05-19 ·

The present invention is directed to compositions including probiotic bacteria in the form of biofilm, wherein the biofilm includes at least two bacterial species. Further provided are a method of using the composition of the invention, and a method of making same.

PROBIOTIC BIOFILM COMPOSITIONS AND METHODS OF PREPARING SAME
20220154134 · 2022-05-19 ·

The present invention is directed to compositions including probiotic bacteria in the form of biofilm, wherein the biofilm includes at least two bacterial species. Further provided are a method of using the composition of the invention, and a method of making same.

Hydrogel prodrug for treatment
11331395 · 2022-05-17 · ·

Aspects of the invention described herein include a hydrogel prodrug and methods of making a hydrogel prodrug for drug delivery. Also contemplated are methods of treating, inhibiting, ameliorating or inhibiting a disease or disorder. Without being limiting, the methods for treatment can be directed to a cancer, HIV, a virus, pain, a bacterial infection, a neurological disorder, hemorrhaging, multiple sclerosis, diabetes, high blood pressure, Alzheimer's, or inhibiting a fungal growth in a subject in need.

Hydrogel prodrug for treatment
11331395 · 2022-05-17 · ·

Aspects of the invention described herein include a hydrogel prodrug and methods of making a hydrogel prodrug for drug delivery. Also contemplated are methods of treating, inhibiting, ameliorating or inhibiting a disease or disorder. Without being limiting, the methods for treatment can be directed to a cancer, HIV, a virus, pain, a bacterial infection, a neurological disorder, hemorrhaging, multiple sclerosis, diabetes, high blood pressure, Alzheimer's, or inhibiting a fungal growth in a subject in need.

TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a S1P modulator.

TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a S1P modulator.

TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a S1P modulator.